PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) has moved one step closer to completing its Dual Gene Therapy Program and the successful identification of its target gene-related to type 2 diabetes and obesity.
The Vancouver-based company announced Tuesday the addition of a potent small interfering RNA (siRNA) construct — which can be used to downregulate a specific targeted gene — to its roster.
The construct has been engineered into what the company calls its Smart-siRNA form and will soon be screened to evaluate its gene silencing capability. If successful, this would bring one aspect of PreveCeutical’s Dual Gene Therapy Program to a close.
READ: PreveCeutical Medical sees positive results from safety appraisal of Sol-Gel formulations in nasal tissue
The design of the Smart-siRNA constructs is done with the final phase of the program in mind, in which the constructs’ biostability will be crucial in assessing preclinical mice models of type 2 diabetes and obesity treatment.
"According to two of the pharmaceutical industry's top analysts, Paul Verdin and Lisa Urquhart of Evaluate Ltd, cell and gene therapy is at one of its most exciting phases of growth and has gained momentum with recent deal making, product sales and interest in the BioPharma sector,” President Mak Jawadekar said in a statement. “With the progress that PreveCeutical has made with its Dual Gene Therapy Program, I believe that PreveCeutical could attract offers from companies in the BioPharma sector for future collaborations and partnerships."
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel